On a roll, Neurocrine nails $575M licensing deal with Abbott

Hot on the heels of a promising package of top-line results from the Phase II trial of their endometriosis therapy, Neurocrine Biosciences (NBIX) has wrapped a $575 million licensing deal for the therapy with Abbott Laboratories. The San Diego-based biotech gets $75 million of that upfront along with Abbott's commitment to fund late-stage clinical investigation work. And there's about $500 million in milestones along with the prospect of royalty payments from an approved product. The deal...

Neurocrine shares skyrocket on promising PhII endometriosis data

Shares of Neurocrine Biosciences soared more than 50 percent in after-markets trading after the San Diego-based developer spelled out the success of a mid-stage trial of elagolix in a population of patients suffering from endometriosis. The gynecological drug hit its co-primary as well as secondary endpoints. Close to two thirds of the patients taking the drug responded to the treatment, with significant reductions in signs of dysmenorrhea, pelvic pain during menstruation, and non-menstrual...